(Date:5/16/2008)...the aftermath of central China,s,earthquake, up to...s, and,over 150,000 were injured. An estimated 10 ...who have lost their homes. With great sorrow for,t...er Ching Hai donated an,additional US$30,000, for ...eme Master Ching Hai International Association mem...
(Date:5/16/2008)...rathyroid hormone readings, study says , ...f vitamin D and high levels of a hormone secreted ... depression in older adults, according to a new re...issue of Archives of General Psychiatry , support... D, depression and other psychiatric illnesses are...
(Date:5/16/2008)... WASHINGTON, May 16 /PRNewswire-USNewswire/ -- Mor...cians in the Greater Portland, Oregon and,Vancouve...contract as,Teamsters., "The Teamsters are please...ontract that gives them job protection and a secur...dent Jim Hoffa., The workers, both full-time and ...
(Date:5/16/2008)... medicine is in a precipitous decline, David C. Da... Physicians (ACP), today joined with leading repr...call for comprehensive reforms to attract, recruit...are physicians. , During a panel discussion of .... Dale and other panelists spoke about the challen...
Breaking Medicine News(10 mins):Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2Health News:Low Vitamin D Tied to Depression in Older Adults 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2...ed that women outlive men in Western countries, an... behavior on the part of men as the reason why.// ...than that. Another reason for the earlier demise o...to parasitic infections. In a report on the study,...
...ization or modernization, the Stress on human life...ey pay attention to the adoption of a more health...-opener for those people with fragile hearts.Most ... concern us.But this one moment of anger is suffic...
...tal new combination of drugs for Hepatitis -C Cure...tandard treatment for the potentially deadly,liver...ive doctors a more potent weapon against the virus...ge in cases of Hepatitis- C liver damage over the...
...there's a firm connection between viral infection ...research has shown that infection with human papil...l cancer. A group of almost 8,500 women with no h...h were followed for ten years. They had a cervical...
Other Medicine News:(Date:5/16/2008)... Presentations at ASCO Annual Meeting Will Further...ns in Front-line Multiple Myeloma -, CAMBRIDGE, M...icals,The Takeda Oncology Company, today announce...scheduled to be featured at the 2008 American Soci...Chicago, Illinois, May 30 -,June 3, 2008. The data...
(Date:5/16/2008)...peakers include industry and customer thought lead...s, Inc., the recognized,leader and trusted resourc...hosted a constellation of prestigious academic med...artners at its annual user group meeting in San,Fr...rs to internally and,collaboratively manage thousa...
(Date:5/16/2008)...ts Include:, -- Results demonstrating that TYKERB... meaningful extension of progression-free survival...tack both the inside and,outside of the HER2 recep...Data demonstrating activity of TYKERB alone despit... of trastuzumab and chemotherapy, LONDON and PHIL...
(Date:5/16/2008)... N.J., May 16 /- Veridex, LLC announc...ry Corporation of America Holdings,(LabCorp), has ...for,prostate cancer. The new assay uses the biolog...cancer, detecting the methylation of the gene,GST-...rs primarily in,cancer. Veridex is developing the ...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 1Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 4Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 1Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 2Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 3Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 4Sleep Apnea Screening Cuts Surgical Complications 17520 1Sleep Apnea Screening Cuts Surgical Complications 17520 2The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 1The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 2The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 3Inquire
Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of Measles IgM antibodies in human serum. For in vitro diagnostic use. High complexity test.
...nzymelinked Immunosorbent Assays(ELISA) is intende... of IgG antibody to Measles Rubeola) virus in huma... the determination of immune status. Paired sera, ...te seroconversion or a significant rise in antibod...
The Diagnostic Automation, Inc. (DAI) Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of IgM antibody to Measles in human serum.
Medicine Products: